טוען...
Treatment with imatinib results in reduced IL-4–producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis
T cells, particularly those producing IL-4, are implicated in inflammation-mediated fibrosis. In our phase I/IIa open-label pilot study in 15 patients with scleroderma-interstitial lung disease (SSc-ILD), high-dose imatinib treatment showed modest improvement in lung function and skin score, but wit...
שמור ב:
| Main Authors: | , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2011
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3221795/ https://ncbi.nlm.nih.gov/pubmed/22015344 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clim.2011.08.010 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|